Treatment Protocol for Lymphoblastic Lymphoma of the European Inter-group Co-operation on Childhood Non-Hodgkin-Lymphoma(EICNHL) - Euro LB 02 protocol

Phase 1

• Conditions: ymphoblastic Lymphoma( malignant disease, pre B- and T cell lymphoma) in children up to 16 years.; MedDRA version: 9.1Level: LLTClassification code 10036545Term: Precursor T-lymphoblastic lymphoma/leukaemia NOS; MedDRA version: 9.1Level: LLTClassification code 10036525Term: Precursor B-lymphoblastic lymphoma NOS

• Registration Number: EUCTR2004-001861-17-NO
• Lead Sponsor: niversity Hospital of Northern Norway. Department of Pediatrics

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2007-02-01
• Last Update Posted: 2 October 2017

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

All newly diagnosed patients under the age of 16 years with a T/pre B cell Non Hodgkin lymfoblastic lymphoma will be included. In Norway all patients will be treated at a Pediatric Oncology ward (University Hospital in Oslo/Rikshospitalet or Ullevål Hospital, Haukeland Hospital, St. Olav Hospital or University Hospital in North Norway, Tromso).
Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

HIV infection or AIDS.
Sever immunodeficiency.
Previous organtransplantation.
Previous malignancy.
Pre-exsiting disease prohibiting chemotherapy as per instructions of this Protocol.
Previous chemotherapy or radiotherapy.
Previous systemic corticosteroid treatment for more than 8 days within two months before the beginning of the therapy in this Protocol.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified